Boston University finds CTE blood marker, but no test yet
A small autopsy-validated study found higher eMTBR-tau levels in former football players with advanced CTE. Researchers say validation is still ahead.
Boston University researchers, working with the nonprofit health system Banner Health, reported on Nov. 19 in the Journal of the American Medical Association that a blood protein called endogenously cleaved microtubule-binding region tau, or eMTBR-tau, was associated with chronic traumatic encephalopathy in former football players.
The study analyzed blood samples from 21 former football players. Eighteen of them were later confirmed to have CTE after death. Those with advanced CTE had significantly higher concentrations of eMTBR-tau than those with early-stage or no CTE. Five participants had both CTE and Alzheimer's disease, and the highest eMTBR-tau levels were found in those individuals.
CTE can currently be diagnosed definitively only by examining brain tissue after death. That constraint has shaped the field: athletes and families who suspect the disease have no way to confirm it while the person is alive, and researchers have lacked a way to identify living patients for studies of potential treatments.
Michael Alosco, a co-senior author of the study and co-director of clinical research at Boston University's CTE Center, called the finding a game-changer. The study is small, and the authors caution that more research is needed to verify the results. The test is not ready for clinical use.
If the findings hold, a blood test could allow doctors to diagnose CTE in living patients for the first time, enabling earlier intervention, better clinical trials, and answers for families who now wait for autopsy confirmation.
The research team was led by Boston University and Banner Health, a nonprofit health care system headquartered in Phoenix.
Sources
More from Science & Climate
Conversation
Reader notes
Loading comments...